BRAF and colorectal carcinoma: Thereby, oxaliplatin-containing adjuvant chemotherapy has been recommended for Stage III CRC patients after curative resection, irrespectively of BRAF status, and to date, BRAF mutation has failed to become a game changer in the treatment of CRCs after curative resection.